Lantheus Holdings, Inc
LNTHLantheus Holdings, Inc. is a global healthcare company specializing in diagnostic and therapeutic solutions for cardiovascular and other diseases. The company develops and markets agents used in medical imaging and treatment, including radio-injectable products that aid in the detection and management of various medical conditions. Founded in 1957, Lantheus is focused on advancing imaging technology to improve patient outcomes.
Company News
Law firm investigating potential securities misconduct for four companies, alleging false statements, misleading financial reporting, and concealment of material facts that impacted stock prices.
The article discusses two small-cap stocks with growth potential, highlighting their performance, risks, and opportunities in the context of potential Federal Reserve interest rate cuts. The Russell 2000 index has risen 5% in the past month, with small-cap stocks showing promise due to interest rate sensitivity and attractive valuations.
Lantheus Holdings reported strong Q4 and full-year 2024 results, with its prostate imaging drug Pylarify becoming a blockbuster. The company also announced two strategic acquisitions to expand its radiopharmaceutical capabilities. Definity maintained its market leadership in ultrasound-enhancing agents.
Lantheus Holdings agreed to acquire Evergreen Theragnostics for $250 million upfront, plus up to $752.5 million in milestone payments, to expand its oncology diagnostic pipeline. The acquisition also adds Neuraceq, an Alzheimer's diagnostic, to Lantheus' portfolio.
Centene (CNC) is expected to benefit from expanding margins in the Marketplace business, contract wins in Medicaid, and improved Medicare Advantage Star ratings.
